These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19814921)

  • 41. Anti-IgE for chronic asthma in adults and children.
    Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003559. PubMed ID: 16625585
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-IgE for chronic asthma in adults and children.
    Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
    Cochrane Database Syst Rev; 2004; (3):CD003559. PubMed ID: 15266491
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation.
    Jurk M; Vollmer J
    BioDrugs; 2007; 21(6):387-401. PubMed ID: 18020622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
    D'Amato G
    Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation.
    Sulaiman I; Lim JC; Soo HL; Stanslas J
    Pulm Pharmacol Ther; 2016 Oct; 40():52-68. PubMed ID: 27453494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Omalizumab: a novel therapy for allergic asthma.
    Davis LA
    Ann Pharmacother; 2004; 38(7-8):1236-42. PubMed ID: 15187202
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunomodulation in asthma: a distant dream or a close reality?
    Bharadwaj A; Agrawal DK
    Int Immunopharmacol; 2004 Apr; 4(4):495-511. PubMed ID: 15099527
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-IgE for chronic asthma.
    Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
    Cochrane Database Syst Rev; 2003; (3):CD003559. PubMed ID: 12917972
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
    Noga O; Hanf G; Brachmann I; Klucken AC; Kleine-Tebbe J; Rosseau S; Kunkel G; Suttorp N; Seybold J
    J Allergy Clin Immunol; 2006 Jun; 117(6):1493-9. PubMed ID: 16751018
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update.
    Holgate S; Buhl R; Bousquet J; Smith N; Panahloo Z; Jimenez P
    Respir Med; 2009 Aug; 103(8):1098-113. PubMed ID: 19362459
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of omalizumab in asthma.
    Price D
    Prim Care Respir J; 2008 Jun; 17(2):62-72. PubMed ID: 18425299
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of omalizumab in the treatment of severe allergic asthma.
    Chapman KR; Cartier A; Hébert J; McIvor RA; Schellenberg RR
    Can Respir J; 2006; 13 Suppl B(Suppl B):1B-9B. PubMed ID: 16909166
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunomodulators and Biologics: Beyond Stepped-Care Therapy.
    Desai M; Oppenheimer J; Lang DM
    Clin Chest Med; 2019 Mar; 40(1):179-192. PubMed ID: 30691711
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potential adverse events with biologic response modifiers.
    Kong JS; Teuber SS; Gershwin ME
    Autoimmun Rev; 2006 Aug; 5(7):471-85. PubMed ID: 16920574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
    Félix Toledo R; Negro Alvarez JM; Miralles López JC
    Allergol Immunopathol (Madr); 2002; 30(2):94-9. PubMed ID: 11958741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Allergens in the pathogenesis of asthma: potential role of anti-immunoglobulin E therapy.
    Storms W
    Am J Respir Med; 2002; 1(5):361-8. PubMed ID: 14720038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of CpG oligonucleotides in treatment of asthma and allergic disease.
    Fonseca DE; Kline JN
    Adv Drug Deliv Rev; 2009 Mar; 61(3):256-62. PubMed ID: 19167442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
    Chipps BE; Figliomeni M; Spector S
    Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy.
    Huang YC; Weng CM; Lee MJ; Lin SM; Wang CH; Kuo HP
    Clin Exp Allergy; 2019 Jan; 49(1):44-53. PubMed ID: 30107059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.